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Abstract
Background: Carcinoma of unknown primary site (CUP) has a poor prognosis and the prognostic factors in these
patients are not well established. Furthermore, there are no selection criteria for patients who should benefit from
chemotherapy.
Methods: The medical records of 179 CUP patients who were treated at Taipei Veterans General Hospital from
2000 to 2009 were reviewed. Factors associated with survival were determined by Kaplan-Meier analysis.
Differences between the groups with and without palliative chemotherapy were analyzed.
Results: Univariate analysis revealed multiple prognostic factors, including performance status, lung metastasis,
number of metastatic organs, serum albumin, corrected serum calcium, lactate dehydrogenase (LDH), sodium, and
cholesterol levels, palliative chemotherapy, and white blood cell and lymphocyte counts. Multivariate analysis
showed that performance status < 2, serum albumin level ≥ 3.5 g/dl, corrected serum calcium level < 10.7 mg/dl,
single metastatic organ, and palliative chemotherapy were independent factors of better prognosis. Patients with
better performance status, higher serum albumin, and lower serum LDH levels had significantly greater benefit
from palliative chemotherapy.
Conclusions: Certain patients with unfavorable CUP will have better survival. Identification of patients with
unfavorable CUP who could benefit from palliative chemotherapy warrants future prospective studies.
Introduction
Cancer of unknown primary site (CUP) is defined as a his-
tologically proven metastatic malignant tumor whose pri-
mary site cannot be identified after thorough pre-
treatment work-up [1]. It is the seventh most prevalent
cancer in the world and the fourth commonest cause of
cancer death in both men and women [2]. CUP accounts
for 2.3%-4.2% of cancers in either gender. Previous studies
suggest that CUP patients should be categorized into
favorable and unfavorable groups before appropriate man-
agement is provided [3-5]. In the favorable group, indivi-
dual treatment according to the possible primary site, such
as poorly differentiated carcinoma with midline distribu-
tion, papillary adenocarcinoma of the peritoneal cavity in
women, adenocarcinoma involving only axillary lymph
nodes in women, and squamous cell carcinoma involving
cervical lymph nodes, achieves longer survival [6]. How-
ever, almost 85% of CUP patients fall into the unfavorable
group, in which chemotherapy is controversial [7]. In last
10 years, further categorization with newly identified prog-
nostic factors, such as Eastern Cooperative Oncology
Group (ECOG) performance status ≥ 2, more than one
organ metastasis, high serum LDH, and low albumin
levels, reflects significantly poor survival within the unfa-
vorable CUP category [7-11]. It remains unknown whether
or not the unfavorable CUP patient with a good prognos-
tic factors is a suitable candidate for palliative chemother-
apy, which may further improve survival. One possible
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treatment outcomes defined between cancer center-based
and registry-based studies [7,8], making meaningful com-
parisons and decisions based on the results difficult. Addi-
tionally, previous studies of single regimens did not make
clear clarification of CUP patients according to the new
prognostic factors [11].
One of the benefits of medical transfer system in Tai-
w a ni st h a tm o s to ft h es u s p e c t e dC U Pp a t i e n t sw i l lb e
referred to a major medical center before a definitive
diagnosis of CUP is made. This phenomenon enables us
to provide more comprehensive evaluation and give pal-
liative chemotherapy, radiotherapy, or new treatment
strategies directed against tumor under the discretion of
the medical oncologists. In this study, we analyzed the
prognostic factors including clinical and biochemical
variables of patients with unfavorable CUP at a single
tertiary medical center. This is the first large retrospec-
tive cohort analysis of unfavorable CUP in Asian popu-
lation. The results of this article might help clinicians to
make better individualized therapeutic plans for the
treatment of patients with unfavorable CUP.
Methods
We reviewed the medical records of Taipei Veterans
General Hospital from January 1
st,2 0 0 0t oD e c e m b e r
31
st,2 0 0 9a n di d e n t i f i e d2 3 0c a s e so fC U P .O ft h e s e ,
30 patients were excluded due to lack of pathologic
confirmation. Another 21 patients were excluded
b e c a u s et h e yh a dd o c u m e n t e df a v o r a b l eC U P ;t h e y
included women with lone axillary lymph nodes con-
taining adenocarcinoma, poorly differentiated or
undifferentiated carcinoma with characteristics of
extragonadal germ cell tumor syndrome, women with
diffuse peritoneal carcinomatosis (papillary adenocarci-
noma), squamous cell carcinoma involving upper cervi-
cal lymph nodes, and squamous cell carcinoma
involving solitary inguinal lymph node. Finally, 179
patients with unfavorable CUP were enrolled for
advanced analysis of prognostic factors and response
to treatment (Figure 1). The ethical approval of this
retrospective study had been done by institutional
review board (IRB), Taipei Veterans General Hospital
with the code number of 2011-03-025IC.
The laboratory parameters were collected within the
period of 1 week before and 2 weeks after the definite
pathologic diagnosis. The corrected serum calcium
levels were calculated as: serum calcium level + 0.8 ×
(4.0 - patient’s albumin level).
The Kaplan-Meier method was used to generate survi-
val curves. Univariate analysis of various parameters for
overall survival was done with the Log rank test, and a
p < 0.05 (two-tailed) was considered significant. Multi-
variate Cox regression analyses were performed subse-
quently using backward, stepwise selection to derive a
multivariate model for significant predictors. Overall
survival was defined as the time from pathological diag-
nosis until either death or last follow-up. The indepen-
dent t test and chi squared test were performed to
evaluate the characteristic differences between che-
motherapy and non-chemotherapy groups, as appropri-
ate. Statistical analyses were done using SPSS software
version 17 (SPSS Inc., Chicago, IL) P <. 0 5w a sc o n s i d -
ered a statistically significant difference.
Figure 1 Patient enrollment. Patient enrollment scheme for unfavorable CUP (cancer of unknown primary site) study.
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Patient characteristics
Of the 179 patients studied, 128 were men (71.5%) and
51 were women (28.5%). Their median age was 73 years
(range, 30-98 years). The clinical and pathological char-
acteristics of the patients are shown in Table 1. The
most common histological diagnoses were unclassifiable
carcinoma (83/179, 46.4%) and adenocarcinoma (71/179,
39.7%); thirty-one (17.3%) patients had histologically
poorly differentiated or undifferentiated carcinoma.
About 52% (93/179) of patients had an ECOG perfor-
mance status ≥ 2. The most common organs in which
tumors were initially diagnosed were bone (26.3%),
lymph nodes (24%), and liver (21.2%). After thorough
imaging studies, lymph nodes, lungs, liver, and bones
were the most frequently involved organs. Approxi-
mately one hundred and eighteen patients (66%)
received palliative chemotherapy. After a median follow-
up of 7.2 months (0.0-64.3 months), the median overall
survival was 6.2 months (0.0-64.3 months). The 1-year
and 2-year survival rates were 37.2% and 23.8%.
Prevalence and mortality rate
In order to see the differences in occurrence rate and
outcome between each year, in Figure 2A, we charted
CUP patient numbers diagnosed yearly from 2000 to
2009 as well as median overall survival of patients diag-
nosed each year in Figure 2B. The case numbers each
year were steady and there was no obvious trend of survi-
val improvement or deterioration during the last decade.
Univariate and multivariate analysis of prognostic factors
The results of univariate analysis are shown in Table 2.
The following clinical variables predicted significantly
shorter overall survival: ECOG performance status ≥ 2
(P < .001), presence of lung metastases (P = .005), ≥ 2
metastatic sites (P = .028), albumin level < 3.5 g/dl (P <
.001), corrected calcium level ≥ 10.7 mg/dl (P = .006),
LDH level ≥ 250 U/L (P = .001), serum sodium level <
135 mmol/l (P < .001), serum cholesterol level < 150
mg/dl (P = .014), and lymphocyte count < 700/μL( P =
.003).
The multivariate analysis of the prognostic factors
identified in the univariate analysis showed ECOG per-
formance status ≥ 2 (hazard ratio [HR], 2.03), albumin <
3.5 g/dl (HR, 2.22), corrected calcium ≥ 10.7 mg/dl (HR,
4.42), multiple (≥ 2) metastatic sites (HR, 1.93) (Table 2)
were statistically significant independent prognostic fac-
tors for shorter survival (Figure 3).
Favorable factors for palliative chemotherapy
Among the patients given palliative chemotherapy, cis-
platin-based regimens accounted for 75.4% of first-line
Table 1 Characteristics of patients with unfavorable
cancer of unknown primary site (n = 179)
Characteristic No. of patients %
Median age at diagnosis, year (range, IQR) 73 (30-98, 58-80)
Gender
Male 128 71.5
Female 51 28.5
Histology
Carcinoma, unclassifiable 83 46.4
Adenocarcinoma 71 39.7
Squamous cell carcinoma 6 3.4
Neuroendocrine carcinoma 12 6.7
Others 7 3.9
Histologic grade
Poorly differentiated or Undifferentiated 31 17.3
Unspecified 148 82.7
Performance status
0 19 10.6
1 67 37.4
2 44 24.6
3 27 15.1
4 22 12.3
Initial site at diagnosis
Liver 38 21.2
Lung 23 12.8
Bone 47 26.3
Central nervous system 7 3.9
Peritoneum 18 10.1
Lymph nodes 43 24
Others 3 1.7
Sites of disease involvement
Liver 80 44.7
Lung and pleural 87 48.6
Bone 74 41.3
Central nervous system 14 7.8
Lymph nodes 107 59.8
No. of metastatic organs
1 40 22.3
2 52 29.1
> 2 87 48.6
Treatment
Chemotherapy 118 66.0
Radiotherapy 52 29.1
Tyrosine kinase inhibitors 2 1.1
Chemotherapy regimens
Cisplatin-based 89 75.4
5-FU-based 51 43.2
Etoposide-based 45 38.1
Gemcitabine-based 17 14.4
Taxane-based 13 11.0
Oxaliplatin-based 11 9.3
IQR, inter-quartile range.
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11.0% were taxane-based regimens. The median overall
survival of the chemotherapy group (n = 118) was 9.2
months, significantly better than the group who did not
receive chemotherapy (n = 61, median survival 1.63
months, P < .001) (Figure 4). The differences between
the two groups are shown in Table 3. The patients who
received palliative chemotherapy were significantly
Figure 2 Case number distribution and survival curve. (A) Case numbers of patients with unfavorable CUP (cancer of unknown primary site)
each year from 2000 to 2009. Thirteen to 24 cases of unfavorable CUP were diagnosed each year. (B) No trend in median overall survival per
diagnosis year was observed.
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primary site (n = 179)
Variable N Median OS, months Univariate P Multivariate
HR 95% CI P
Age, years
< 65 60 5.33 .309
≥ 65 119 6.47
Gender
Male 128 5.63 .467
Female 51 6.47
Performance status 2.025 1.294-3.168 .002
0-1 86 13.37 < .001
2-4 93 3.47
Body mass index
< 24 83 5.33 .223
≥ 24 53 11.8
Histology
Adenocarcinoma 71 4.47 .402
Carcinoma, unspecified 83 6.47
Squamous cell carcinoma 6 59.7
Others 19 11.1
Histologic grade
Poorly differentiated or Undifferentiated 31 7.03 .869
Unspecified 148 5.63
Liver metastases
Yes 80 5.1 .236
No 99 7.7
Lung metastases
Yes 87 4.43 .005
No 92 9.2
Bone metastases
Yes 74 5.33 .255
No 105 6.43
Lymph node metastases
Yes 107 6.17 .658
No 72 6.47
No. of metastatic organs 1.927 1.147-3.237 .013
1 40 18.07 .028
≥ 2 139 5.33
Radiotherapy
Yes 52 11.1 .105
No 127 5.07
Chemotherapy 3.211 2.009-5.132 < .001
Yes 118 9.2 < .001
No 61 1.63
Albumin 2.216 1.440-3.409 < .001
< 3.5 g/dl 66 2.77 < .001
≥ 3.5 g/dl 113 11.1
Estimated creatinine clearance
< 60 ml/min 75 6.43 .806
≥ 60 ml/min 74 6.17
Corrected Ca level 4.421 1.529-12.784 .006
< 10.7 mg/dl 171 6.47 .006
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patients who did not receive chemotherapy and had bet-
ter performance status (P < .001), higher serum albumin
levels (P = .002), and lower LDH levels (P = .01). Histo-
logical type or grade, number of metastatic sites, and
corrected serum calcium level did not differ between the
two groups.
Discussion
The median overall survival of CUP patients was only 3-
4 months before the 1990s.
2,3 Recent studies identified
several independent prognostic variables to predict the
outcomes of patients with unfavorable CUP. Culine et al
used performance status and serum LDH levels to build
a prognostic index. The survival significantly differed
between good and poor prognostic groups (median sur-
vival, 11.7 vs. 3.9 months, P < .0001) [7]. Seve et al used
albumin level and liver metastasis to separate patients
with unfavorable CUP into two subgroups. The low-risk
group had median survival of 371 days compared to the
poor-risk group that had median survival of 103 days (P
< .0001) [9]. In the current study, in addition to the fac-
tors such as serum albumin level, performance status
and number of metastatic sites, which are in consensus
with previous studies [7-17], we identified two new
independent prognostic factors among patients with
unfavorable CUP, corrected serum calcium level (≥ 10.7
mg/dl), an indicator of poor outcome, and palliative
chemotherapy, an indicator of better outcome. There
are plenty of etiologies to induce hypercalcemia in can-
cer patients, such as osteoclastic metastases to bone,
secretion of parathyroid hormone (PTH)- related pep-
tides by tumor cells, or excessive vitamin D produced
by tumors. Dismal prognoses related to hypercalcemia
are observed in solid tumors and hematological malig-
nancies [18-20]. Thus, hypercalcemia in cancer patients
could universally indicate advanced illness, no matter
what the primary site is.
Despite the ever-growing advances of chemotherapeu-
tic agents in the last decade, the management of patients
with unfavorable CUP remains a challenge for clinicians
[21]. Recently, Kodaira et al analyzed 58 CUP patients
treated with unified chemotherapy containing carbopla-
tin and paclitaxel [11]. The overall response rate was as
high as 34.5% and median overall survival was 16.7
months. Although their study did not exclude women
with peritoneal carcinomatosis or adenocarcinoma,
which belongs in the favorable CUP group, the high
Table 2 Univariate and multivariate analysis of overall survival (OS) of patients with unfavorable cancer of unknown
primary site (n = 179) (Continued)
≥ 10.7 mg/dl 6 0.57
Lactate dehydrogenase
< 250 U/L 76 10.67 .001
≥ 250 U/L 102 3.67
Na
< 135 mmol/l 55 2.07 < .001
≥ 135 mmol/l 124 9.0
Cholesterol
< 150 mg/dl 56 4.07 .014
≥ 150 mg/dl 110 9.2
Alkaline phosphatase
< 100 U/L 80 7.03 .569
≥ 100 U/L 99 5.63
WBC count (× 10
3 cells/μL)
< 10.0 124 10.27 < .001
> 10.0 55 3.23
Lymphocyte count
< 700/μL 17 2.67 .003
≥ 700/μL 162 7.03
Hemoglobin level
< 11 g/dl 67 5.33 .091
≥ 11 g/dl 112 7.73
Platelet count
< 150 × 10
9/L 33 4.87 .82
≥ 150 × 10
9/L 146 6.43
HR, hazard ratio; CI, confidence interval; WBC, white blood cell.
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without adenocarcinoma (n = 32) could still imply a
benefit for aggressive chemotherapy. In another cancer
registry-based study done by Seve et al, overall survival
was not associated significantly with chemotherapy, but
marked improvement of survival in patients at cancer
c e n t e r sc o m p a r e dt ot h o s ew h ow e r en o tc o u l da l s o
imply a potential benefit for aggressive surveillance and
treatment [8]. In the study by Culine et al, the role of
chemotherapy was not analyzed even though the
authors pursued the need to design a prospective trial
to prove the survival benefit of palliative chemotherapy
[7]. On the other hand, the meta-analysis done by Golfi-
nopoulos et al reviewing multiple treatment regimens
for CUP indicated that there was no single type of che-
motherapy solidly proven to prolong the survival of
patients with unfavorable CUP, although using platinum
and taxane-based regimens showed possible trends of
survival benefit. One limitation of this meta-analysis is
that of the 10 enrolled trials published from 1980 to
2009, only four trials excluded at least some patients
subsets with good prognoses [22]. In the current study,
the possible survival benefit of palliative chemotherapy
for certain patients with unfavorable CUP was observed
and, thus, warrants further prospective studies. As
shown in Table 3, it is interesting to find that patients
receiving chemotherapy were significantly younger, had
higher serum albumin, lower serum LDH levels, and
better ECOG performance status. The above characteris-
tics reflected the consideration of physicians for whether
or not palliative chemotherapy rather than hospice care
would benefit the patients with unfavorable CUP. It is
not surprising that patients given chemotherapy were
significantly younger than those who were not. When
patients with unfavorable CUP presented with hypoalbu-
minemia, it was an indication of poor nutritional status,
cachexia, and ongoing weight loss, and thus, discouraged
the physician to administer chemotherapy [23-25]. LDH
Figure 3 Significant prognostic factors to overall survival in multivariate analysis. Kaplan-Meier survival curves for patients with
unfavorable CUP with (A) ECOG performance status of 0-1 vs. 2-4 (13.37 vs. 3.47 months; P = .002). (B) Albumin ≥ 3.5 g/dl vs. < 3.5 g/dl (11.1 vs.
2.77 months; P < .001). (C) Metastasis to single organ vs. multiple organs (18.07 vs. 5.33 months; P = .013). (D) Corrected calcium level ≥ 10.7
mg/dl vs. < 10.7 mg/dl (0.57 vs. 6.47 months; P = .006).
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ing tumor masses and is related to the tumor burden
itself [26]. In the current study, poorer performance sta-
tus was also associated with higher serum LDH levels
(chi squared, p = .015) and was an indication not to
administer chemotherapy. However, the histology sub-
types were not independent prognostic factors in unfa-
vorable subgroup of CUPs. (Table 2) Also, there were
no significant differences in the distribution of variable
histology groups between with and without chemother-
apy treatment groups. It means that the histology type
might not influence the judgement of clinician to give
chemotherapy or not, and also did not influence
survival.
The limitations of our study include its retrospective
cohort design, the elderly median age (73 years) of the
cohort, which was older than in other articles (60 years)
[3], and male predominance (71.5%). This could be
attributed to the patients’ types found in a veterans’ hos-
pital. Besides, neuroendocrine carcinoma of unknown
primary (NCUP) were not excluded in the unfavorable
CUP group during data collection. Despite it is categor-
ized into favorable CUP in the literatures, but NCUP
also constituted of a heterogeneous cohort with variable
Figure 4 Chemotherapy and prognosis. Kaplan-Meier survival curves of patients with unfavorable CUP who received chemotherapy or not:
yes vs. no (9.2 vs. 1.63 months; P = .001).
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published series. In the latest literature review of NCUP,
the median overall survival is 15.5 months[27].In our
database, the median overall survival of NCUP in the
chemotherapy group is 11.1 months, and in the mean-
while, the median overall survival of all unfavorable
CUP in chemotherapy group is 9.2 months. In our
study, the prognosis of NCUP treated with palliative
chemotherapy was not significantly better than other
CUPs. This may account for why we did not exclude
this group of patients in unfavorable CUP. Finally, the
chemotherapy regimens were not unified, so it is diffi-
cult to compare the efficacy between specific drugs.
However, the variety of treatment regimens could also
reflect the lack of standard treatment guidelines for
treatment of unfavorable CUP at present [22].
Conclusion
In conclusion, our study identified several independent
prognostic factors in patients with unfavorable CUP. It
also demonstrated that better performance status, higher
serum albumin levels, and lower LDH levels may influ-
ence the decision of the clinican to give palliative che-
motherapy, which might be associated with longer
survival in unfavorable CUP patients. This study provide
further characterization of patients with unfavorable
CUP. Whether selection of individuals who would bene-
fit from chemotherapy warrants prospective studies in
the future.
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